A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
A comparison of the sarcopenic effect of androgen receptor-axis-targeted agents vs. androgen deprivation alone in patients with metastatic prostate cancer
CONCLUSIONS: Although we found no significant difference in the sarcopenic effects of GnRH alone, GnRH with abiraterone, or GnRH with enzalutamide in our cohort of 55 hormone-naive metastatic prostate cancer patients, overall decreases in muscle mass were observed for all three groups. This highlights the importance of muscle-retaining strategies for patients undergoing ADT for metastatic prostate cancer, regardless of therapeutic regimen.PMID:37581552 | PMC:PMC10426421 | DOI:10.5489/cuaj.8245 (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - August 15, 2023 Category: Urology & Nephrology Authors: Tarek Lawen Kaveh Masoumi-Ravandi Ricardo A Rendon Liette Connor Ross J Mason Source Type: research
